Seeking Alpha
 

Enanta Pharmaceuticals, Inc. (ENTA)

- NASDAQ
  • Thu, Feb. 5, 12:26 PM
    • Enanta Pharmaceuticals (ENTA -1.6%) FQ1 results: Revenues: $77.5M (+999%); R&D Expense: $4.5M (+4.7%); SG&A: $2.8M (+33.3%); Operating Income: $70.2M (+999%); Net Income: $42M (+877.8%); EPS: $2.18 (+826.7%); Quick Assets: $104M (+14.5%).
    • No guidance given.
    | 1 Comment
  • Thu, Feb. 5, 7:49 AM
    • Enanta Pharma (NASDAQ:ENTA): FQ1 EPS of $2.18 misses by $1.64.
    • Revenue of $77.5M (+8607.9% Y/Y) misses by $6.64M.
    • Press Release
    | 7 Comments
  • Nov. 24, 2014, 8:06 AM
    • Enanta Pharmaceuticals (ENTA -1.1%) FQ4 results: Revenues: $2.6M (+100.0%); Operating Expenses: $8M (+31.1%); Operating Loss: ($5.3M) (-12.8%); Net Loss: ($5M) (-13.6%); Loss Per Share: ($0.27) (-8.0%).
    • FY2014 results: Revenues: $47.7M (+48.6%); Operating Expenses: $28.8M (+25.2%); Operating Income: $19M (+111.1%); Net Income: $34.4M (+621.2%); EPS: $1.80 (+368.7%); Quick Assets: $90.8M (-10.5%).
    • No guidance given.
    | Comment!
  • Nov. 24, 2014, 7:36 AM
    • Enanta (NASDAQ:ENTA): FQ4 EPS of -$0.27 beats by $0.06.
    • Revenue of $2.64M (+95.6% Y/Y) misses by $1.17M.
    • Press Release
    | Comment!
  • Nov. 23, 2014, 5:30 PM
  • Aug. 11, 2014, 9:31 AM
    • Enanta Pharmaceuticals (NASDAQ:ENTA) fiscal Q3 results: Revenues: $42.1M (+999%); Operating Expenses: $7.2M (+22.8%); Operating Income: $34.9M (+935.2%); Net Income: ($50.1M) (+999%); EPS: ($2.61) (+999%); Quick Assets: $95.9M (-5.5%).
    • No financial guidance given.
    | Comment!
  • Aug. 11, 2014, 8:00 AM
    • Enanta (NASDAQ:ENTA): FQ3 EPS of $2.61 may not be comparable to consensus of $1.67.
    • Revenue of $42.1M (+2451.5% Y/Y) beats by $1.27M.
    • Press Release
    | Comment!
  • May. 12, 2014, 8:18 AM
    • Enanta Pharmaceuticals (ENTA): FQ2 EPS of -$0.28 misses by $0.74.
    • Revenue of $2.2M (+80.6% Y/Y) misses by $5.95M.
    • Press Release
    | Comment!
  • Feb. 13, 2014, 8:27 AM
    • Enanta (ENTA): FQ1 EPS of -$0.30 misses by $0.15.
    • Revenue of $0.9M misses by $0.51M.
    • Press Release
    | Comment!
  • Jan. 31, 2014, 9:46 AM
    • AbbVie (ABBV) +3.5% in early trading despite reporting a 27% Y/Y drop in Q4 earnings, as the company releases positive results on its final-phase clinical trials for a promising new drug to treat certain patients with hepatitis C.
    • ABBV says it is on track to begin major regulatory submissions of the drug early in Q2.
    • ABBV’s blockbuster drug Humira eclipsed $10B in sales in 2013, making it the highest-grossing drug in the world; sales of the drug rose 13.4% during Q4 to $3.04B.
    • Overall net sales fell 1.8% to $5.11B, despite the Humira figures; sales of its Niaspan, TriCor and Trilipix cholesterol drugs fell by nearly 90% because of the introduction of generics..
    • Sees FY 2014 EPS of $3.00-$3.10 vs $3.16 analyst consensus estimate and revenue of $19B vs. $19.12B consensus; results exclude any potential revenue from the expected 2014 launch of the hepatitis C drug.
    • Shares of Enanta Pharmaceuticals (ENTA +14%), a close ABBV partner, are up sharply.
    | 1 Comment
  • Nov. 25, 2013, 7:48 AM
    • Enanta Pharmaceuticals (ENTA): FQ4 EPS of -$0.25.
    • Revenue of $1.34M. (PR)
    | Comment!
  • Aug. 12, 2013, 2:34 PM
    • Enanta Pharmaceuticals (ENTA +6%) moves up after beating FQ3 estimates earlier this morning.
    • EPS losses came in at $0.23 per share, on revenues of $1.6M.
    • Analysts expected loss per share of $0.31.
    • In the same period last year, net loss was $3.5M, or $4.31 per share, on revenues of $2.5M.
    • Cash and equivalents totaled $114.8M at the end of June, compared to $45.4M on September 30, 2012.
    • The company expects that its current cash, cash equivalents and marketable securities will be sufficient to meet anticipated requirements for at least the next 24 months.
    | Comment!
  • Aug. 12, 2013, 7:41 AM
    • Enanta Pharmaceuticals (ENTA): FQ3 EPS of -$0.23 beats by $0.11.
    • Revenue of $1.65M beats by $0.92M. (PR)
    | Comment!
  • May. 8, 2013, 8:36 AM
    Enanta Pharmaceuticals (ENTA): FQ2 EPS of -$2.28 misses by $1.94. Revenue of $1.2M misses by $3.43M. (PR)
    | Comment!
Visit Seeking Alpha's
ENTA vs. ETF Alternatives
Company Description
Enanta Pharmaceuticals Inc is a biotechnology company. It is engaged in the research and development of small molecule drugs for infectious diseases. The Company uses its chemistry-driven approach & drug discovery capabilities to develop its products.
Sector: Healthcare
Industry: Biotechnology
Country: United States